Endothelin antagonists in diabetic nephropathy: back to basics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

1. Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review.Cureus · 2021
   Review
2. Association between Endothelin-1 Levels and Kidney Disease among Blacks.Journal of the American Society of Nephrology : JASN · 2017
   Article
3. Endothelin.Pharmacological reviews · 2016
   Review
4. What is damaging the kidney in lupus nephritis?Nature reviews. Rheumatology · 2016
   Review
5. Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner.PloS one · 2015
   Article

Corrections and comments

• Comment on
  HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction.2014
• Comment on
  Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis.2014

Authors and funding

2 authors at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as